Search for a report

GLOBAL GENE THERAPY MARKET FORECAST 2022-2030

  • You are here:
  • Home
  • Downloads
  • GLOBAL GENE THERAPY MARKET FORECAST 2022-2030

GLOBAL GENE THERAPY MARKET FORECAST 2022-2030

The global gene therapy market is likely to reach $xx million by 2030, growing at a CAGR of xx% during the forecast period. The market study has also analyzed the impacts of COVID-19 on the gene therapy industry qualitatively and quantitatively.

GLOBAL GENE THERAPY MARKET FORECAST 2022-2030

Global Gene Therapy Market by Therapy (in Vivo, Ex Vivo) Market by Vector Type (Adeno Virus Vector, Adeno-associated Virus Vector, Lentiviral Vector, Retroviral Vector, Herpes Virus Vector, Other Vector Types) Market by Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth Factors, Receptors, Other Gene Types) Market by End User (Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Diseases) by Geography

Request free sample

The global gene therapy market is likely to reach $xx million by 2030, growing at a CAGR of xx% during the forecast period. The market study has also analyzed the impacts of COVID-19 on the gene therapy industry qualitatively and quantitatively.

Gene Therapy Market

To learn more about this report, request a free sample copy

Gene therapy is one of biotech’s most significant achievements in the twenty-first century. With the growing number of treatments in development and recent approvals, it has become a critical development area in the biotech industry. In developed countries, gene therapy is more universally accepted than in developing countries. Gene therapy has seen a tremendous surge in clinical uses, particularly in cancer treatment.

Key enablers of the global gene therapy market growth are:

  • Prevalence of target diseases
  • Advancements in molecular biology
    • The advancements in gene therapy have enabled greater adoption, and this trend is expected to continue over the forecast period and consequently contribute to the growth of the market studied.
    • Recombinant adeno-associated virus (rAAV)-based vectors are currently the most extensively utilized gene therapy products in development. They have the greatest promise for the delivery of gene therapy indications. While the bulk of AAV-based therapeutic items (about 74 percent) are still in early to mid-stage clinical development, several encouraging clinical outputs have aided in moving the pipeline of potential AAV-based therapies forward.
    • For example, In 2018, UniQure Biopharma BV sponsored the trial of AMT-061 in severe or moderately severe Hemophilia B patients, and AMT-061 is a recombinant adeno-associated viral vector.
  • Investments in the R&D activities related to gene therapies
  • Favorable regulatory environment

Key growth restraining factors are:

  • Absence of reliable vector production
    • Vector is the most important part of any gene therapy, and several modern medicines, notably Luxturna, are based on recombinant adeno-associated viruses (rAAVs). The spike in interest has resulted in a surge in demand for clinical-grade rAAV preparations, leaving several companies trying to find a dependable vector supply. Companies lose potential while rAAV demand remains unmet, patient access to existing medicines is limited, and developmental plans for new gene-therapeutic substances stop.
  • High cost of gene therapies
  • Lack of standard regulations, coverage, and approval processes

Global Gene Therapy Market | Top Trends

  • Due to sustained funding, the number of advanced therapy medicinal products (ATMP) clinical studies has exploded, with the overall number of trials increasing from 486 in 2015 to 1,028 at the end of 2018. CART treatments represent a particularly fast-growing market within the cell and gene therapy pipeline landscape.
  • According to the FDA, a considerable rise in developmental new drug (IND) applications indicates a surge in cell and gene therapy tapping new early development. Based on this activity, the authorities predict that the number of cell and gene therapy product approvals will increase in the future years.
  • Another factor that is expected to contribute to the bright future of viral vectors is the increasing spread of rare diseases. The number of patients being diagnosed with rare diseases is increasing. It is placing more attention toward gene therapy to treat these diseases, as currently, there is a lack of availability for such treatments. The growing burden of rare diseases is one of the prime fueling factors for the future of viral vector-based gene therapy.

Market Segmentation – Therapy, Vector Type, Gene Type, and End Use –

Market by Therapy:

  • In Vivo
  • Ex Vivo

Market by Vector Type:

  • Adeno Virus Vector
  • Adeno-Associated Virus Vector
  • Lentiviral Vector
  • Retroviral Vector
    • Retroviruses have many benefits over other viral vectors on the market. Retroviruses, for example, can be handy when persistent gene transfer is necessary.
    • A retrovirus’s most important property is to convert it from a single-stranded RNA genome into a double DNA molecule that can incorporate into the target cell’s genome. It suggests that retroviral vectors can be utilized to permanently alter the nuclear genome of the host cell.
  • Herpes Virus Vector
  • Other Vector Types

Market by Gene Type:

  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth Factors
  • Receptors
  • Other Gene Types

Market by End Use:

  • Oncological Disorders
  • Rare Diseases
    • Government initiatives in granting speedy approval as well as government support for research and development to hasten diagnosis and early treatments of rarer and undiagnosed illnesses are major factors driving the segment’s growth.
    • Furthermore, government agencies such as the National Institutes of Health (NIH) have launched a program called “Therapeutics for Rare and Neglected Diseases” (TRND), which aims to scale up gene-vector manufacturing and disseminate best practices to gain regulatory approval for new gene therapies in collaborative efforts with biotech and academic groups.
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Other Diseases

Geographical Study Based on Four Major Regions:

  • North America: The United States and Canada
    • North America led the industry and is a key player in cell and gene therapy adoption. Following the approval of pharmaceuticals in the United States in 2017, the market in North America grew more quickly, and funding from worldwide began to pour into clinical trials in the region.
    • To enter the North American market, many vendors began acquiring smaller businesses. The Alliance for Regenerative Medicine plays a vital role in regulating cell & gene therapy products. It is constantly insisting on the reimbursement pathway for gene therapy treatments, which will increase the number of patients opting for cell & gene therapy treatments in the region.
    • However, the US provides the maximum number of various cell & gene therapy treatments across the globe, and many patients travel across countries to the US to avail treatment.
  • Europe: The United Kingdom, Germany, France, Italy, Spain, Belgium, Poland, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific
  • Rest of World: Latin America, Middle East & Africa

The major players in the global gene therapy market are:

  • Amgen
  • Novartis
  • Kite Pharma (Gilead)
  • Spark Therapeutics

Key strategies adopted by some of these companies:

Novartis acquired CellforCure from LFB, including its cell and gene manufacturing facility located in Les Ulis, France, in April 2019.

In June 2019, European Commission (EC) granted conditional marketing authorization to Bluebird bio Inc.’s ZYNTEGLO, gene therapy for patients (12 years and older) with transfusion-dependent β-thalassemia.

In the same month, a clinical-stage gene therapy company, Nightstar Therapeutics, was acquired by Biogen for approximately $ 800 million. The company is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.

Report Synopsis:

Report Scope Details
Market Forecast Years 2022-2030
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Vector Type, Therapy, End Use, Gene Type
Geographies Analyzed North America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

Abeona Therapeutics, Amgen Inc, Applied Genetic Technologies Corporation, Biogen Inc, Bluebird Bio Inc, Celgene, Epeius Biotechnologies, Gilead Sciences Inc, GlaxoSmithKline Plc, Juno Therapeutics, Kite Pharma Inc, Newlink Genetics Corp, Novartis AG, Orchard Therapeutics, Oxford Biomedica, Sanofi, Sibiono GeneTech Co Ltd, Spark Therapeutics Inc, Transgene SA, Uniqure NV

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • KEY DRIVERS
      • PREVALENCE OF TARGET DISEASES
      • ADVANCEMENTS IN MOLECULAR BIOLOGY
      • INVESTMENTS IN THE R&D ACTIVITIES RELATED TO GENE THERAPIES
      • FAVORABLE REGULATORY ENVIRONMENT
    • KEY RESTRAINTS
      • ABSENCE OF RELIABLE VECTOR PRODUCTION
      • HIGH COST OF GENE THERAPIES
      • LACK OF STANDARD REGULATIONS, COVERAGE, AND APPROVAL PROCESSES
  1. KEY ANALYTICS
    • IMPACT OF COVID-19 ON GENE THERAPY MARKET
    • KEY MARKET TRENDS
    • PORTER’S FIVE FORCES ANALYSIS
      • BUYERS POWER
      • SUPPLIERS POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • PATENT ANALYSIS
  2. MARKET BY THERAPY
    • IN VIVO
    • EX VIVO
  3. MARKET BY VECTOR TYPE
    • ADENO VIRUS VECTOR
    • ADENO-ASSOCIATED VIRUS VECTOR
    • LENTIVIRAL VECTOR
    • RETROVIRAL VECTOR
    • HERPES VIRUS VECTOR
    • OTHER VECTOR TYPES
  4. MARKET BY GENE TYPE
    • ANTIGEN
    • CYTOKINE
    • TUMOR SUPPRESSOR
    • SUICIDE
    • DEFICIENCY
    • GROWTH FACTORS
    • RECEPTORS
    • OTHER GENE TYPES
  5. MARKET BY END USE
    • ONCOLOGICAL DISORDERS
    • RARE DISEASES
    • CARDIOVASCULAR DISEASES
    • NEUROLOGICAL DISORDERS
    • INFECTIOUS DISEASES
    • OTHER DISEASES
  6. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • ITALY
        • SPAIN
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • THAILAND
        • VIETNAM
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    • KEY STRATEGIC DEVELOPMENTS
      • MERGERS & ACQUISITIONS
      • PRODUCT LAUNCHES & DEVELOPMENTS
      • PARTNERSHIPS & AGREEMENTS
      • BUSINESS EXPANSIONS & DIVESTITURES
    • COMPANY PROFILES
      • ABEONA THERAPEUTICS
      • AMGEN INC
      • APPLIED GENETIC TECHNOLOGIES CORPORATION
      • BIOGEN INC
      • BLUEBIRD BIO INC
      • CELGENE
      • EPEIUS BIOTECHNOLOGIES
      • GILEAD SCIENCES INC
      • GLAXOSMITHKLINE PLC
      • JUNO THERAPEUTICS
      • KITE PHARMA INC
      • NEWLINK GENETICS CORP
      • NOVARTIS AG
      • ORCHARD THERAPEUTICS
      • OXFORD BIOMEDICA
      • SANOFI
      • SIBIONO GENETECH CO LTD
      • SPARK THERAPEUTICS INC
      • TRANSGENE SA
      • UNIQURE NV

LIST OF TABLES  

TABLE 1: MARKET SNAPSHOT – GENE THERAPY

TABLE 2: GLOBAL GENE THERAPY MARKET, BY THERAPY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: GLOBAL GENE THERAPY MARKET, BY THERAPY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: GLOBAL IN VIVO MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: GLOBAL IN VIVO MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: GLOBAL EX VIVO MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: GLOBAL EX VIVO MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: GLOBAL ADENO VIRUS VECTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: GLOBAL ADENO VIRUS VECTOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: GLOBAL ADENO-ASSOCIATED VIRUS VECTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: GLOBAL ADENO-ASSOCIATED VIRUS VECTOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: GLOBAL LENTIVIRAL VECTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 15: GLOBAL LENTIVIRAL VECTOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 16: GLOBAL RETROVIRAL VECTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 17: GLOBAL RETROVIRAL VECTOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 18: GLOBAL HERPES VIRUS VECTOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 19: GLOBAL HERPES VIRUS VECTOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 20: GLOBAL OTHER VECTOR TYPES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 21: GLOBAL OTHER VECTOR TYPES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 22: GLOBAL GENE THERAPY MARKET, BY GENE TYPE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 23: GLOBAL GENE THERAPY MARKET, BY GENE TYPE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 24: GLOBAL ANTIGEN MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 25: GLOBAL ANTIGEN MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 26: GLOBAL CYTOKINE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 27: GLOBAL CYTOKINE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 28: GLOBAL TUMOR SUPPRESSOR MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 29: GLOBAL TUMOR SUPPRESSOR MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 30: GLOBAL SUICIDE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 31: GLOBAL SUICIDE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 32: GLOBAL DEFICIENCY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 33: GLOBAL DEFICIENCY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 34: GLOBAL GROWTH FACTORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 35: GLOBAL GROWTH FACTORS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 36: GLOBAL RECEPTORS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 37: GLOBAL RECEPTORS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 38: GLOBAL OTHER GENE TYPES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 39: GLOBAL OTHER GENE TYPES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 40: GLOBAL GENE THERAPY MARKET, BY END USE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 41: GLOBAL GENE THERAPY MARKET, BY END USE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 42: GLOBAL ONCOLOGICAL DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 43: GLOBAL ONCOLOGICAL DISORDERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 44: GLOBAL RARE DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 45: GLOBAL RARE DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 46: GLOBAL CARDIOVASCULAR DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 47: GLOBAL CARDIOVASCULAR DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 48: GLOBAL NEUROLOGICAL DISORDERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 49: GLOBAL NEUROLOGICAL DISORDERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 50: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 51: GLOBAL INFECTIOUS DISEASE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 52: GLOBAL OTHER DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 53: GLOBAL OTHER DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 54: GLOBAL GENE THERAPY MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 55: GLOBAL GENE THERAPY MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 56: NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 57: NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 58: EUROPE GENE THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 59: EUROPE GENE THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 60: ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 61: ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 62: REST OF WORLD GENE THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 63: REST OF WORLD GENE THERAPY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 64: LIST OF MERGERS & ACQUISITIONS

TABLE 65: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 66: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 67: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES 

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: GLOBAL GENE THERAPY MARKET, GROWTH POTENTIAL, BY THERAPY, IN 2021

FIGURE 6: GLOBAL GENE THERAPY MARKET, BY IN VIVO, 2022-2030 (IN $ MILLION)

FIGURE 7: GLOBAL GENE THERAPY MARKET, BY EX VIVO, 2022-2030 (IN $ MILLION)

FIGURE 8: GLOBAL GENE THERAPY MARKET, GROWTH POTENTIAL, BY VECTOR TYPE, IN 2021

FIGURE 9: GLOBAL GENE THERAPY MARKET, BY ADENO VIRUS VECTOR, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL GENE THERAPY MARKET, BY  ADENO-ASSOCIATED VIRUS VECTOR, 2022-2030 (IN $ MILLION)

FIGURE 11: GLOBAL GENE THERAPY MARKET, BY LENTIVIRAL VECTOR, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL GENE THERAPY MARKET, BY RETROVIRAL VECTOR, 2022-2030 (IN $ MILLION)

FIGURE 13: GLOBAL GENE THERAPY MARKET, BY HERPES VIRUS VECTOR, 2022-2030 (IN $ MILLION)

FIGURE 14: GLOBAL GENE THERAPY MARKET, BY OTHER VECTOR TYPES, 2022-2030 (IN $ MILLION)

FIGURE 15: GLOBAL GENE THERAPY MARKET, GROWTH POTENTIAL, BY GENE TYPE, IN 2021

FIGURE 16: GLOBAL GENE THERAPY MARKET, BY ANTIGEN, 2022-2030 (IN $ MILLION)

FIGURE 17: GLOBAL GENE THERAPY MARKET, BY CYTOKINE, 2022-2030 (IN $ MILLION)

FIGURE 18: GLOBAL GENE THERAPY MARKET, BY TUMOR SUPPRESSOR, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL GENE THERAPY MARKET, BY SUICIDE, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL GENE THERAPY MARKET, BY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL GENE THERAPY MARKET, BY GROWTH FACTORS, 2022-2030 (IN $ MILLION)

FIGURE 22: GLOBAL GENE THERAPY MARKET, BY RECEPTORS, 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL GENE THERAPY MARKET, BY OTHER GENE TYPES, 2022-2030 (IN $ MILLION)

FIGURE 24: GLOBAL GENE THERAPY MARKET, GROWTH POTENTIAL, BY END USE, IN 2021

FIGURE 25: GLOBAL GENE THERAPY MARKET, BY ONCOLOGICAL DISORDERS, 2022-2030 (IN $ MILLION)

FIGURE 26: GLOBAL GENE THERAPY MARKET, BY RARE DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 27: GLOBAL GENE THERAPY MARKET, BY CARDIOVASCULAR DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 28: GLOBAL GENE THERAPY MARKET, BY NEUROLOGICAL DISORDERS, 2022-2030 (IN $ MILLION)

FIGURE 29: GLOBAL GENE THERAPY MARKET, BY INFECTIOUS DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 30: GLOBAL GENE THERAPY MARKET, BY OTHER DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 31: NORTH AMERICA GENE THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 32: UNITED STATES GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 33: CANADA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: EUROPE GENE THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED KINGDOM GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: GERMANY GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: FRANCE GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: ITALY GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: SPAIN GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: BELGIUM GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: POLAND GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: REST OF EUROPE GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: ASIA-PACIFIC GENE THERAPY MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 44: CHINA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: JAPAN GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 46: INDIA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: SOUTH KOREA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 48: INDONESIA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: THAILAND GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 50: VIETNAM GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 51: AUSTRALIA & NEW ZEALAND GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 52: REST OF ASIA-PACIFIC GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 53: REST OF WORLD GENE THERAPY MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 54: LATIN AMERICA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

FIGURE 55: MIDDLE EAST & AFRICA GENE THERAPY MARKET, 2022-2030 (IN $ MILLION)

  1. MARKET BY THERAPY
    • IN VIVO
    • EX VIVO
  2. MARKET BY VECTOR TYPE
    • ADENO VIRUS VECTOR
    • ADENO-ASSOCIATED VIRUS VECTOR
    • LENTIVIRAL VECTOR
    • RETROVIRAL VECTOR
    • HERPES VIRUS VECTOR
    • OTHER VECTOR TYPES
  3. MARKET BY GENE TYPE
    • ANTIGEN
    • CYTOKINE
    • TUMOR SUPPRESSOR
    • SUICIDE
    • DEFICIENCY
    • GROWTH FACTORS
    • RECEPTORS
    • OTHER GENE TYPES
  4. MARKET BY END USE
    • ONCOLOGICAL DISORDERS
    • RARE DISEASES
    • CARDIOVASCULAR DISEASES
    • NEUROLOGICAL DISORDERS
    • INFECTIOUS DISEASES
    • OTHER DISEASES
  5. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • ITALY
        • SPAIN
        • BELGIUM
        • POLAND
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • THAILAND
        • VIETNAM
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    To request a free sample copy of this report, please complete the form below:

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now